Gilead's sofosbuvir wins over EU panel; TetraLogic ditches $103.5M IPO;

@FierceBiotech: Avalon jumpstarts first biotech in $500M GlaxoSmithKline portfolio deal. Article | Follow @FierceBiotech

@JohnCFierce: Lots of biotech startup news this month. Lots of deal flow in the pipeline. | Follow @JohnCFierce

@DamianFierce: Meet LEE011, Novartis's overnight celebrity breast cancer candidate. News | Follow @DamianFierce

@EmilyMFierce: Eli Lilly, Project A.L.S. forge preclinical drug discovery pact. Story | Follow @EmilyMFierce

> Another day, another biotech pulling the plug on an IPO, this time TetraLogic Pharmaceuticals and its planned $103.5 million raise. News

> Europe's Committee for Medicinal Products for Human Use (CHMP) is recommending approval of Gilead Sciences' ($GILD) promising hepatitis C drug sofosbuvir, which would sell as Sovaldi. More

> The FDA has terminated one of its advisory panels, canning the Veterinary Medicine Advisory Committee, which hadn't met in three years. Article

> Struggling Ariad ($ARIA) got some good news in the EU, as regulators there are allowing Iclusig to stay on the market, albeit with some tougher restrictions. Story

Medical Device News

@FierceMedDev: Myriad partners up with BioMarin for cancer diagnostics. Yesterday's story | Follow @FierceMedDev

@MarkHFierce: OraSure dumped Roche in favor of Thermo Fisher for a drug testing Dx development deal. Strategic, not fickle. Yesterday's story | Follow @MarkHFierce

@MichaelGFierce: FDA allows pivotal trial of Actinium's armed-antibody isotope delivery. More from FierceDrugDelivery | Follow @MichaelGFierce

> Covidien plans $18M Florida expansion as it cuts and reorganizes elsewhere. Story

> Cyberonics shares climb again after fruitful Q2. Article

> J&J now mulling three bids for Ortho Clinical Dx division. More

> Judge cautions that unscrupulous attorneys may exploit J&J hip settlement. Item

Pharma News

@FiercePharma: Thursday's best-read special report: Top 10 Patent Losses of 2014. Report | Follow @FiercePharma

@EricPFierce: Pfizer says it will close a Puerto Rico plant days after Merck says the same thing. Story | Follow @EricPFierce

@CarlyHFierce: Biogen Idec's MS pill Tecfidera wins 10 years' protection in EU. Analysts expect 36% of $4.5B in 2018 sales to come from non-U.S. More | Follow @CarlyHFierce

> Ariad's Iclusig further restricted by EMA. Story

> Novartis plans $5B share buyback, hints at restructuring. Article

> EU patent call sets stage for Tecfidera launch in Europe. Report

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.